Home » Stocks » TRVN

Trevena, Inc. (TRVN)

Stock Price: $2.37 USD -0.14 (-5.58%)
Updated December 1, 4:00 PM EST - Market closed
Pre-market: $2.35 -0.02 (-0.84%) Dec 2, 4:20 AM

Stock Price Chart

Key Info

Market Cap 372.16M
Revenue (ttm) 3.03M
Net Income (ttm) -23.94M
Shares Out 157.03M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $2.37
Previous Close $2.51
Change ($) -0.14
Change (%) -5.58%
Day's Open 2.45
Day's Range 2.37 - 2.49
Day's Volume 3,477,569
52-Week Range 0.48 - 3.26

More Stats

Market Cap 372.16M
Enterprise Value 266.14M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 157.03M
Float n/a
EPS (basic) -0.23
EPS (diluted) -0.22
FCF / Share -0.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 23.66M
Short Ratio 5.11
Short % of Float n/a
Beta 2.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 122.78
PB Ratio 3.30
Revenue 3.03M
Operating Income -23.94M
Net Income -23.94M
Free Cash Flow -21.07M
Net Cash 106.02M
Net Cash / Share 0.68
Gross Margin 1.02%
Operating Margin -789.87%
Profit Margin -789.90%
FCF Margin -695.05%
ROA -16.74%
ROE -32.85%
ROIC -155.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(121.52% upside)
Current: $2.37
Target: 5.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-99.46%---40%---83.29%-
Gross Profit0.035.73-3.756.25-0.130.81
Operating Income-26.58-30.50-70.39-102-50.62-49.95-23.35-15.61
Net Income-24.87-30.78-71.87-103-50.53-49.70-23.25-15.64
Shares Outstanding91.6873.5659.4452.4043.7924.660.790.67
Earnings Per Share-0.27-0.42-1.21-1.97-1.15-2.02-29.71-23.70
Operating Cash Flow-23.67-25.38-71.26-91.55-40.08-39.78-24.24-14.81
Capital Expenditures--0.17-3.50-0.61-0.38-0.44-0.14-0.02
Free Cash Flow-23.67-25.54-74.75-92.16-40.45-40.22-24.38-14.83
Cash & Equivalents37.1162.7967.5111217310738.086.95
Total Debt13.4617.4028.1818.3318.191.70-4.87
Net Cash / Debt23.6545.3839.3393.4715510538.082.08
Book Value30.0841.5334.6378.5814399.20-81.57-59.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Trevena, Inc.
Country United States
Employees 24
CEO Carrie L. Bourdow

Stock Information

Ticker Symbol TRVN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TRVN
IPO Date January 31, 2014


Trevena, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.